Key Takeaways
- A brutal quarter, but the bottom is in: Volumes held roughly flat YoY (26,820 MT vs 27,358 MT) despite a global demand contraction, while management declared prices have "bottomed up" and should not fall further.
- China dumping crushed specialty chemical realizations: Oversupply from China, driven by its own sluggish domestic demand, combined with stockpiling in developed markets to hammer offtake and pricing, forcing the shutdown of the Acetonitrile plant and idling DMF at 40-45% capacity.
- The expansion playbook is intact, just delayed: All major projects are progressing, but timelines have slipped by 1-3 quarters; the n-Butylamine plant is now due December 2023, Methylamine by June 2024, and the DME plant by end of FY2025.
- DME is the high-stakes wildcard: Management's personal view is that the 100,000-ton Dimethyl Ether plant will be a "big game changer," contingent on a government order mandating 25% DME blending in LPG that is expected in "two to three weeks."
- What to watch next quarter: Whether the promised government DME blending order materializes, any sign of price normalization from the bottom, and progress on the n-Butylamine plant commissioning timeline.
Demand & Pricing Environment
- Global demand contraction: The specialty chemical industry faced an "unparalleled array of hurdles" as swift global demand contraction met oversupply from China, where sluggish domestic demand pushed product into export markets at distressed prices. Developed markets also slowed due to prior stockpiling.
- Volume resilience: Total volumes were more or less maintained at 26,820 MT (vs 27,358 MT YoY) because of the company's diversified product basket, though new capacities being added have not yet reflected in increased volumes.
- Price bottoming declared: Management stated prices have bottomed and should not go further down, with improvement expected from here. Normalization to stable, normal levels is expected by the last quarter of the current financial year, though not to the elevated levels of FY21-22.
- Volume recovery underway: Quantities lifting has already started improving. People have become habituated to lower prices, so the move from lower to higher prices takes longer, but higher quantities have started moving.
- Pharma and agrochemical improvement: The API and pharma market (over 55-60% of exposure) and agrochemical market have seen quantities moving more than earlier quarters; only prices need to improve.
- Lean inventory strategy: After a "very bad taste" from inventory in the last 1.5-2 quarters, the company now runs very lean inventories of only 15-20 days of raw materials, so it neither benefits nor loses from raw material price fluctuations.
Ram Reddy: "Definitely the current situation has bottomed up. I don't think the prices will go further down. We see from here onwards, there should be some improvement and maybe in coming one quarters or two quarters, prices should be stable at normal level from these bottoms."
Product-Level Challenges
- Acetonitrile plant shut down: Production stopped for the last 1.5 quarters because prices fell below raw material cost. Demand still exists but is met by imported acrylonitrile by-product. An anti-dumping case has been filed; if it succeeds, the company may restart.
- DMF running at 40-45% capacity: Two problems constrained DMF: sometimes unfavorable prices, and sometimes insufficient DMA feedstock. The Methylamine plant commissioning will solve the DMA shortage. Dumping from both Saudi Arabia and China below raw material prices is hurting the domestic market, and the company is not getting government support for antidumping.
- DMC and Propylene Glycol at 25-30% capacity: Battery manufacturers were supposed to start 2-2.5 quarters back but no company has actually begun battery production. China has created huge capacities and is selling at losses. The company is running at minimum capacity for domestic availability, while REACH registration has enabled marketing outside Europe with a couple of ISO tanks shipped.
- DMF exports begin: The company has started exporting DMF to markets where people stopped buying from China, including the USA, after obtaining REACH registration.
- Cost advantage in core Amines: Having been in the Amines market for more than 25 years, the company's cost price is lower than anybody else, "probably in the world," enabling exports of products including Methylamine to various parts of the world.
Ram Reddy: "Actually dumping is happening in the country. Very unfortunate we are not getting government support for the antidumping."
Expansion Projects & Timelines
- All expansions progressing: Management has not taken the current situation as permanent and has not stopped expansions, though timelines have slipped by 1-3 months here and there.
- n-Butylamine plant: Capacity of 15,000 tons per annum; commissioning expected around December 2023, delayed from the earlier September timeline due to equipment and labour shortages. The company is the only domestic producer, with domestic demand around 8,000 metric tons. Expects to sell 8,000-9,000 tons in the first year and reach 100% capacity in two years.
- Methylamine plant: Capacity of 40,000 tons; commissioning expected around June 2024, delayed from the earlier March 2024 guidance.
- Dimethyl Ether plant: Capacity of 100,000 tons per annum; likely commissioned by end of FY2025, delayed from the earlier July 2024 guidance.
- DMAHCL plant: Capacity of 7,500 tons; likely commissioned by end of H2 FY2024.
- Unit 4: Currently executing phase 2 and 3 projects; shaping up as a world-class facility, set to begin phased production from H2 FY24 onwards.
- DMF expansion on back bench: Not scrapped but deferred; the company wants to give time for the market to absorb and settle to full capacity of present capacity first.
- Balaji Specialty Chemicals debottlenecking: 90% of equipment has reached the plant; remaining 10% expected in one week. A three-week shutdown will be taken to install additional columns to increase capacity and improve purity.
- Balaji Specialty Chemicals new land: Received a provisional letter, paid 25% EMD, expecting final letter today. Within 7-8 days, will submit details for environmental clearance. New products planned include Hydrogen Cyanide, Sodium Cyanide, EDTA, Dimethyl malonate, and others, some first time in the country and some listed in the PLI scheme.
- Balaji Specialty Chemicals capacity doubling deferred: Not doubling capacity until the plant reaches 100% capacity utilization with full price support.
Ram Reddy: "We have not taken the current situation as a permanent thing. We have not stopped our expansions. All the expansions, maybe one or two months here and there, are progressing as decided earlier."
DME: The Game-Changer Bet
- Government blending mandate: About a month back, the government initiated that LPG companies should mix 25% DME into LPG. An order is expected in the coming two to three weeks, and the government has instructed BIS to check storages for DME compatibility.
- Massive addressable market: One or two districts alone have more than 60,000-70,000 tons of LPG consumption. Even 20-30% of that market is not sufficient to meet demand, positioning DME as a potentially transformative product for the company.
- Successful vehicle trial: A trial was done with one vehicle at the Automotive Research Center in Pune (an Innova), which gave good results. The government has given more positive signals on Dimethyl Ether than on DMC blending.
- DMC blending stalled: The company is still corresponding with the government of India on DMC blending in diesel, but the government is not fully confident on DMC blending.
- Battery opportunity in early stages: The company is in advanced discussions with both Amara Raja and Exide, with samples sent to one company. Discussions cover NMP and part of DMC, but no timeline was provided for when battery manufacturers would start their plans.
- Three more carbonates on hold: Technology for three more carbonates is ready, but the company will not proceed until battery manufacturing actually starts.
Ram Reddy: "I feel, it is my personal view, the Dimethyl Ether should be big game changer for the company."
Financial Targets & Capital Allocation
- Revenue targets: FY24-25: plus or minus INR 3,000 crores. FY26-27: INR 4,000 crores, based on reference prices as on date.
- EBITDA margin guidance: Between 20% to 22% on a consolidated basis.
- Export target: Minimum 20%-22% exports, balance 78%-80% domestic. The current standalone mix is 85/15 domestic/export; no specific timeline was given for achieving the target mix.
- Balaji Specialty Chemicals funding: Majority from internal accruals; may require INR 100-200 crores if projects are not delayed. If installations proceed faster, may borrow INR 100-120 crores from banks or take help of the parent company.
- Balaji Specialty Chemicals IPO withdrawn: The IPO was deferred due to current market situation and valuation not meeting expectations. The next course of action is expected in the coming quarters. The management team's engagement in the IPO process temporarily hampered their availability to complete preparation of financial results for consolidation.
- Capacity utilization targets: DMF: minimum 60%-70%. DMC and PG: minimum 50%-60% before the end of this year.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| n-Butylamine plant commissioning | 15,000 tons capacity | December 2023 |
| Methylamine plant commissioning | 40,000 tons capacity | June 2024 |
| DME plant commissioning | 100,000 tons capacity | End of FY2025 |
| DMAHCL plant commissioning | 7,500 tons capacity | End of H2 FY2024 |
| Unit 4 phased production start | Phase 2 and 3 projects | H2 FY24 onwards |
| Price normalization to normal levels | From current bottomed-out levels | Last quarter of current financial year |
| DMF capacity utilization | Minimum 60%-70% | No specific timeline |
| DMC and PG capacity utilization | Minimum 50%-60% | Before end of this year |
| n-Butylamine first-year sales | 8,000-9,000 tons | First year of operation |
| n-Butylamine full capacity | 100% utilization | Within two years of commissioning |
| Revenue target | INR 3,000 crores (plus or minus) | FY24-25 |
| Revenue target | INR 4,000 crores | FY26-27 |
| Consolidated EBITDA margin | 20% to 22% | Ongoing |
| Export mix target | Minimum 20%-22% | No specific timeline given |
| DME government blending order | 25% DME in LPG mandate | Expected in 2-3 weeks from call date |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue from operations | ₹469.32 cr, vs ₹674.86 cr in Q1 FY23 |
| Total volume | 26,820 metric tons, vs 27,358 metric tons in Q1 FY23 |
| EBITDA | ₹103.69 cr, vs ₹219.48 cr in Q1 FY23 |
| EBITDA margin | 22.09%, vs 32.52% in Q1 FY23 |
| PAT | ₹67.68 cr, vs ₹148.04 cr in Q1 FY23 |
| Diluted EPS | ₹16.28 per equity share, vs ₹37.95 in Q1 FY23 |
| Amines volume | 6,757 metric tons |
| Amines derivatives volume | 8,288 metric tons |
| Specialty chemicals volume | 11,775 metric tons |
| Standalone debt | Zero debt |
| Overall average capacity utilization | 60% to 70% of total installed capacity |
| DMF capacity utilization | 40% to 45% |
| DMC and Propylene Glycol capacity utilization | 20% to 25% |
| Ethylamine capacity utilization | More than 90% |
| Export share (standalone) | 15%, with a target of 20% to 22% going forward |
| Pharma end-user exposure | More than 55% to 60% |
| Agrochemical end-user exposure | Around 25% to 26% |
| Revenue target for FY24-25 | Plus or minus ₹3,000 cr, on stable normal pricing levels |
| Revenue target for FY26-27 | ₹4,000 cr, on stable normal pricing levels |